FDA Pediatric Advisory Committee Meets on Post-Marketing Pediatric-Focused Safety Reviews

The U.S. Food and Drug Administration's Pediatric Advisory Committee holds a virtual public meeting at 10 a.m. ET on Sept. 16 to discuss post-marketing pediatric-focused safety reviews as required under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act of 2003 (PREA).